November 18, 2016 - By Clifton Ray · 0 Comments
The stock of Usana Health Sciences Incorporated (NYSE:USNA) registered a decrease of 2.99% in short interest. USNA’s total short interest was 677,700 shares in November as published by FINRA. Its down 2.99% from 698,600 shares, reported previously. With 62,000 shares average volume, it will take short sellers 11 days to cover their USNA’s short positions. The short interest to Usana Health Sciences Incorporated’s float is 14.98%. About 17,054 shares traded hands. USANA Health Sciences, Inc. (NYSE:USNA) has declined 0.25% since April 18, 2016 and is downtrending. It has underperformed by 4.68% the S&P500.
USANA Health Sciences, Inc. develops and makes science nutritional and personal care products. The company has a market cap of $1.53 billion. It operates as a direct selling firm in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia. It has a 15.51 P/E ratio. The Company’s USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of body nutrition for every age group.
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.09, from 0.9 in 2016Q1. The ratio dropped, as 11 funds sold all USANA Health Sciences, Inc. shares owned while 51 reduced positions. 21 funds bought stakes while 35 increased positions. They now own 4.92 million shares or 4.65% less from 5.16 million shares in 2016Q1.
Blue Bell Private Wealth Mngmt Lc holds 500 shares or 0.04% of its portfolio. Royal Bank & Trust Of Canada has 3,080 shares for 0% of their US portfolio. Usa Finance Portformulas accumulated 0.32% or 10,349 shares. Old Mutual Invsts (Uk) Limited has 59,105 shares for 0.12% of their US portfolio. First Trust Limited Partnership has invested 0% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA). Wells Fargo Mn holds 0% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA) for 11,649 shares. The New York-based Focused Wealth Mngmt Inc has invested 0.02% in USANA Health Sciences, Inc. (NYSE:USNA). Shell Asset Management, a Netherlands-based fund reported 3,691 shares. Nordea Investment Mgmt has 5,092 shares for 0% of their US portfolio. Comml Bank Of Mellon has 0% invested in the company for 90,386 shares. Blackrock Fund Advsr holds 0% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA) for 128,141 shares. Aqr Capital Management Ltd, a Connecticut-based fund reported 44,732 shares. Ahl Prtnrs Ltd Liability Partnership has 29,801 shares for 0.18% of their US portfolio. Advsrs Asset Mgmt has invested 0% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA). Paradigm Asset Management Ltd Liability Co has 0% invested in the company for 5,900 shares.
Insider Transactions: Since June 3, 2016, the stock had 0 insider purchases, and 23 sales for $24.67 million net activity. 9,104 shares were sold by Brown Jim, worth $1.20 million. On Monday, August 1 FULLER GILBERT A sold $117,739 worth of the stock or 859 shares. 10,000 shares were sold by WENTZ MYRON W, worth $1.24M on Wednesday, November 9. 1,058 shares were sold by Woo Deborah, worth $148,120. Another trade for 10,000 shares valued at $1.25M was made by WENTZ DAVE on Friday, June 3. $1.23 million worth of shares were sold by Bramble James on Monday, August 15. $1.35 million worth of USANA Health Sciences, Inc. (NYSE:USNA) was sold by Gull Global Ltd.
Out of 3 analysts covering USANA Health Science (NYSE:USNA), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. USANA Health Science has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Wednesday, August 5, the company rating was upgraded by Pivotal Research. The firm earned “Buy” rating on Wednesday, September 16 by DA Davidson. DA Davidson downgraded it to “Neutral” rating and $180 target price in Thursday, August 6 report. The firm earned “Buy” rating on Friday, October 16 by Sidoti.
USANA Health Sciences, Inc., incorporated on July 20, 1992, develops and makes science nutritional and personal care products. The Firm has activities in approximately 20 markets across the world. The Firm operates as a direct selling firm in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions, which include Southeast Asia Pacific, Greater China and North Asia. Southeast Asia Pacific comprises Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand and Indonesia. Greater China includes Hong Kong, Taiwan and China. North Asia comprises Japan and South Korea. The Company’s product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. The Company’s USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately 13 months age. The USANA Nutritionals Essentials products include USANA Essentials and HealthPak 100. The Company’s Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. These products support needs, such as cardiovascular health, skeletal/structural health and digestive health, and are intended to be used in conjunction with the Essentials. The Optimizers products include Proflavanol, CoQuinone 30 and BiOmega-3.
More recent USANA Health Sciences, Inc. (NYSE:USNA) news were published by: Businesswire.com which released: “USANA Health Sciences Reports Record Net Sales of $233.2 Million; 41% Increase …” on August 04, 2015. Also Businesswire.com published the news titled: “USANA Health Sciences’ China Subsidiary, BabyCare Ltd., Receives Approval for …” on May 12, 2016. Businesswire.com‘s news article titled: “USANA Health Sciences Reports First Quarter Financial Results” with publication date: May 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray